Zydus Lifesciences Limited has announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2026. The company reported a significant 29% year-on-year growth in revenue from operations for the second quarter of FY27, reaching Rs. 79,096 million. For the first half of FY27, revenue from operations increased by 25% to Rs. 1,59,266 million.
Zydus Lifesciences Announces Q2 and H1 FY27 Financial Highlights
Zydus Lifesciences Limited has released its unaudited consolidated financial results for the second quarter (Q2) and the first half (H1) of the financial year 2027, ending on September 30, 2026. The company demonstrated robust performance across key financial metrics.
Q2 FY27 Performance
For the quarter ended September 30, 2026, Zydus Lifesciences reported a revenue from operations of Rs. 79,096 million, marking a substantial 29% increase compared to the same period last year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the quarter stood at Rs. 18,945 million. The company’s Net Profit for the quarter was Rs. 9,255 million.
Key highlights for Q2 FY27 include:
- Revenue from operations: Rs. 79,096 million (up 29% y-o-y)
- EBITDA: Rs. 18,945 million (down 6% y-o-y)
- Net Profit: Rs. 9,255 million (down 27% y-o-y)
- Capex (organic): Rs. 4,655 million
H1 FY27 Performance
In the first half of FY27, the company’s revenue from operations reached Rs. 1,59,266 million, showing a 25% growth year-on-year. EBITDA for the half year was Rs. 38,239 million, while Net Profit stood at Rs. 18,859 million.
Key highlights for H1 FY27 include:
- Revenue from operations: Rs. 1,59,266 million (up 25% y-o-y)
- EBITDA: Rs. 38,239 million (down 7% y-o-y)
- Net Profit: Rs. 18,859 million (down 31% y-o-y)
- Capex (organic): Rs. 10,530 million
The Net Debt to Equity ratio as of September 30, 2026, was reported at 0.19x, with a Net Debt to EBITDA ratio of 0.62x.
Business Segment Updates
The announcement also provided a breakdown of business-wise sales performance. For Q2 FY27, the Pharma Business contributed significantly with revenues of Rs. 64,075 million, up 22.1% year-on-year. The Consumer Wellness segment saw substantial growth, with revenues of Rs. 11,223 million, an increase of 76.1% y-o-y. The MedTech segment also performed well, with revenues of Rs. 2,246 million, up 47% y-o-y.
In H1 FY27, the Pharma Business generated Rs. 1,24,975 million, a 15.1% increase. The Consumer Wellness segment grew by 71.0% to Rs. 25,515 million, and MedTech revenues surged by 226.9% to Rs. 5,074 million.
Innovation and Operations
The company highlighted updates on its innovation pipeline, including progress in NCE Research with Saroglitazar Magnesium trials and Biotech R&D, receiving approval for Phase III clinical trials for a monoclonal antibody. Updates on operations included the conclusion of USFDA inspections and approval for a transdermal patch product. The earnings call to discuss these results was scheduled for November 4, 2026.
Source: BSE
